Prevalence of Latent Tuberculosis Infection in Persons with and Without Human Immunodeficiency Virus Infection Using Two Interferon-gamma Release Assays and Tuberculin Skin Test in a Low Human Immunodeficiency Virus Prevalence, Intermediate...
Overview
Microbiology
Authors
Affiliations
Background: The risk of tuberculosis (TB) is higher in human immunodeficiency virus (HIV)-infected patients and intravenous drug users (IDUs). We determined the prevalence and risk factors of latent TB infection (LTBI) in individuals with or without HIV infection, including IDUs, in a country with a low HIV prevalence, an intermediate TB burden, and a high Bacillus Calmette-Guérin (BCG) vaccine coverage using two interferon-gamma release assays (IGRAs) and the tuberculin skin test (TST).
Methods: For this prospective, cross-sectional study, HIV-infected and -uninfected patients from a regional hospital and medical center in Taiwan were enrolled. Results of the two IGRAs [QuantiFERON-TB Gold (QFT-G) and QuantiFERON-TB Gold In-Tube (QFT-GIT)] and the TST were compared. Risk factors for positivity were analyzed.
Results: We recruited 233 patients [198 (85%) men; mean age, 39.4 years]. Most patients (74%) were BCG vaccinated. The prevalence of LTBI was estimated to be 22.8% by TST, 15.9% by QFT-G, and 20.6% by QFT-GIT. HIV-infected individuals had fewer positive QFT-GIT [7.0% vs. 28.6%, p < 0.001, adjusted odds ratio (aOR) = 0.28, p = 0.05] and TST results, and more indeterminate QFT-G responses (9.3% vs. 0.7%, p = 0.002). Concordance between IGRAs and TST was very poor in HIV-infected patients (κ < 0.05). Independent risk factors for IGRA positivity were increasing age (QFT-G: aOR = 1.98, p = 0.03; QFT-GIT: aOR = 2.00, p = 0.01) and IDUs (aOR = 4.33, p = 0.05 by QFT-G).
Conclusion: HIV-infected persons had a significantly lower response to both IGRAs and TST. High discordance was found between the two generations of IGRAs and between IGRAs and TST. Increasing age, a known risk factor for LTBI, was significantly associated with IGRAs, but not with TST.
Mashiri C, Batidzirai J, Chifurira R, Chinhamu K Trop Med Infect Dis. 2024; 9(7).
PMID: 39058196 PMC: 11281671. DOI: 10.3390/tropicalmed9070154.
Wang K, Zhao J, Feng X, He S, Li J, Sun F RMD Open. 2024; 10(1).
PMID: 38233074 PMC: 10806639. DOI: 10.1136/rmdopen-2023-003503.
Matulyte E, Kancauskiene Z, Kausas A, Urboniene J, Lipnickiene V, Kopeykiniene J Pathogens. 2023; 12(8).
PMID: 37623950 PMC: 10459141. DOI: 10.3390/pathogens12080990.
Njagi L, Nduba V, Mureithi M, Mecha J BMJ Open Respir Res. 2023; 10(1).
PMID: 37197794 PMC: 10193057. DOI: 10.1136/bmjresp-2022-001581.
Zhang Y, Lu P, Wu K, Zhou H, Yu H, Yuan J Front Cell Infect Microbiol. 2023; 13:1051060.
PMID: 36960041 PMC: 10029977. DOI: 10.3389/fcimb.2023.1051060.